FDA clears Nucletron's new VCMC Applicator for gynecologic cancers

During the first day of the annual conference for the American Society for Radiation Oncology (ASTRO) in Miami, Nucletron, an Elekta company, today announced that it has received FDA 510(k) clearance for its new Vaginal CT/MR Multi Channel (VCMC) Applicator, offering a brachytherapy solution that enables very precise dose delivery for gynecologic cancers. Combined with Oncentra® treatment planning software this applicator makes it possible to reach new levels of workflow optimization.

"Our new vaginal applicator has been developed to fulfill the wish of many radiotherapists to deliver the radiation dose where it matters most, with greater precision. Thanks to a unique design featuring channels which follow the curve of the applicator tip, health care providers can now deliver radiation directly to the target area, while sparing surrounding healthy tissues," says Jos Lamers, Executive Vice President, Elekta Brachytherapy Solutions. "The recent results of the PORTEC-2 study underlined the role of brachytherapy in preventing cancer recurrence in women following surgery for uterine cancer, while resulting in significantly lower side effects, and significantly better quality of life. The new VCMC will allow health care teams to build on these results in treating women with gynecologic cancers."

Bringing the right dose to the right place is critical in successful vaginal brachytherapy. The Vaginal CT/MR Multi Channel Applicator provides accurate target coverage and maximizes conformity in the treatment of gynecologic cancers. It features Nucletron's Precise Dose Delivery Solution (PDDSTM) technology, an innovative system that loads several source channels in the applicator, with a unique catheter geometry. This results in a dwell position that is very close to the target area, allowing for greater treatment precision. This applicator is designed to optimize the dose distribution to help prevent recurrence, while minimizing toxicity, side effects and impaired quality of life.

The VCMC Applicator is easy to assemble, clean and sterilize and integrates seamlessly with Nucletron's Oncentra treatment planning software. Automatic reconstruction of the exact geometry of the applicator dramatically improves the speed of planning, and ensures precise and reproducible placement of the applicator.

Source:

Nucletron

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Elekta. (2023, September 12). FDA clears Nucletron's new VCMC Applicator for gynecologic cancers. News-Medical. Retrieved on November 22, 2024 from https://www.news-medical.net/news/20111003/FDA-clears-Nucletrons-new-VCMC-Applicator-for-gynecologic-cancers.aspx.

  • MLA

    Elekta. "FDA clears Nucletron's new VCMC Applicator for gynecologic cancers". News-Medical. 22 November 2024. <https://www.news-medical.net/news/20111003/FDA-clears-Nucletrons-new-VCMC-Applicator-for-gynecologic-cancers.aspx>.

  • Chicago

    Elekta. "FDA clears Nucletron's new VCMC Applicator for gynecologic cancers". News-Medical. https://www.news-medical.net/news/20111003/FDA-clears-Nucletrons-new-VCMC-Applicator-for-gynecologic-cancers.aspx. (accessed November 22, 2024).

  • Harvard

    Elekta. 2023. FDA clears Nucletron's new VCMC Applicator for gynecologic cancers. News-Medical, viewed 22 November 2024, https://www.news-medical.net/news/20111003/FDA-clears-Nucletrons-new-VCMC-Applicator-for-gynecologic-cancers.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Elekta striving to build radiation therapy infrastructures and save lives of cancer patients in Africa